Company Information

BAFNA PHARMACEUTICALS LTD.

NSE : BAFNAPHBSE : 532989ISIN CODE : INE878I01022Industry : Pharmaceuticals & DrugsHouse : Private
BSE87.300 (0 %)
PREV CLOSE ( ) 87.30
OPEN PRICE ( ) 87.30
BID PRICE (QTY) 84.85 (1)
OFFER PRICE (QTY) 87.30 (41)
VOLUME 10
TODAY'S LOW / HIGH ( )87.30 87.30
52 WK LOW / HIGH ( )76.5 125.55
NSE85.15-2.35 (-2.69 %)
PREV CLOSE( ) 87.50
OPEN PRICE ( ) 85.15
BID PRICE (QTY) 85.20 (23)
OFFER PRICE (QTY) 86.95 (10)
VOLUME 275
TODAY'S LOW / HIGH( ) 85.10 85.50
52 WK LOW / HIGH ( )75.9 124.45
ChairmanShanmugam Hemalatha
Company SecretaryVishnu Vasudeva Kuppa
Non Executive Independent DirectorP K Sundaresan
B Kamlesh Kumar
R Chitra
Krishna Yeachuri
Non Independent & Non Executive DirectorAkila Chintalapati Raju
Upendar Mekala Reddy
Whole Time Director - OperationsVinayak Dinesh Dendukuri
Incorporation Year : 1995

Registered Office :

Address : Bafna Towers,New No 68, Old No.299,Thambu Chetty Street Chennai,
Tamil Nadu-600001 .

Phone : 044- 25267517 / 25270992 / 42677555

Email :  info@bafnapharma.com 

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE,MCX

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.